三力制药与海南大学签署技术转让合同，拓展创新药产品布局

Core Viewpoint - The company has signed a technology transfer contract with Hainan University to acquire the patent application rights for the HXW2324 compound, aimed at developing a new treatment for Alzheimer's disease, enhancing its innovative drug product portfolio and market competitiveness [1][2]. Group 1: Technology Transfer Agreement - The total transfer price for the patent rights is set at 200 million RMB, which includes a milestone payment of 20 million RMB and a sales commission of 180 million RMB [2]. - The initial milestone payment of 3 million RMB is contingent upon Hainan University conducting efficacy studies on the HXW2324 compound using three classic Alzheimer's disease animal models, with results needing mutual agreement for further research [2][3]. Group 2: Project Terms and Conditions - The project can be terminated by either party if deemed unnecessary, and sales commissions will be paid at a rate of 2 RMB per box (including VAT) until the total sales commission reaches 180 million RMB or five years have passed since the first commission withdrawal [3]. - The company has indicated that the contract's execution will not significantly impact its financial status or operating performance for the current year, although drug development is inherently risky and subject to various unpredictable factors [3]. Group 3: Company Strategy and Brand Image - The company has changed its stock abbreviation from "Guizhou Sanli" to "Sanli Pharmaceutical" to better reflect its main business and strengthen its brand image [4]. - The company has established a biopharmaceutical fund with a total scale of 500 million RMB, focusing on equity investment projects in biotechnology and health management, aiming to build a comprehensive investment ecosystem in the innovative drug sector [4].